Related Experiment Video

Updated: Jun 1, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Neuroendocrine activation as a target of modern chronic heart failure pharmacotherapy

Łukasz Dobrek1, Piotr Thor

  • 1Department of Pathophysiology, Jagiellonian University, Medical College 18 Czysta St. 31-121 Kraków, Poland. lukaszd@mp.pl

Acta Poloniae Pharmaceutica
|June 9, 2011
PubMed

Insights

Chronic heart failure (CHF) treatment is advancing with new drugs targeting neurohormonal mechanisms beyond traditional therapies. Novel strategies include vasopressin receptor antagonists and endothelin receptor antagonists for improved CHF management.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure (CHF) pathophysiology understanding and treatment are rapidly evolving.
  • Current CHF pharmacotherapy involves complex regimens targeting the renin-angiotensin-aldosterone system (RAAS), beta-blockers, diuretics, and vasodilators.

Purpose of the Study:

  • To describe the modern approach to systemic treatment of chronic heart failure (CHF).
  • To highlight novel therapeutic strategies being introduced into CHF pharmacology.

Main Methods:

  • Review of current and emerging pharmacotherapies for chronic heart failure.
  • Description of agents targeting novel neurohormonal mechanisms activated in CHF.

Main Results:

  • Established CHF treatments include RAAS inhibitors, beta-blockers, diuretics, and vasodilators.
  • Emerging therapies include vasopressin receptor antagonists (VRAs), endothelin receptor antagonists (ERAs), neutral endopeptidase inhibitors (NEPI), vasopeptidase inhibitors (VPI), and anticytokines agents like Etanercept.

Conclusions:

  • Significant efforts are underway to introduce novel therapeutic strategies for CHF.
  • The modern approach to CHF systemic treatment incorporates a broader range of neurohormonal targets.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...